Lumex Instruments - Laboratory Analytical Equipment manufacturer Logo
Unit 1-3 7294 Fraserview Place, Mission, B.C., V4S 0A3, Canada V4S 0A3 Unit 1-3 7294 Fraserview Place, Mission, B.C., V4S 0A3 Canada
+1 604-820-8085, +1 604 820-4486, sales@lumexinstruments.com

Lumex Instruments

Insight into mysteries of Nature
  • COVID-19 Detection System
  • Analytical equipment
  • Analytical equipment
  • Analytical equipment
  • Analytical equipment

Products

Lumex Instruments YouTube channel

Recombinant therapeutic monoclonal antibodies. Determination of product-related impurities according to USP 129 and Ch.P 3127

Recombinant therapeutic monoclonal antibodies. Determination of product-related impurities according to USP 129 and Ch.P 3127 Lumex Instruments 740

INTRODUCTION

The present method is used for the determination of product-related impurities in recombinant therapeutic monoclonal antibodies (Immunoglobulin G, IgG) according to United States Pharmacopoeia general chapter 129 (Analytical Procedures for Recombinant Therapeutic Monoclonal Antibodies, Capillary SDS electrophoresis) using CAPEL-205 capillary electrophoresis system. Alternatively, the determination of IgG impurities in accordance with Chinese Pharmacopoeia general chapter 3127 (Monoclonal antibodies – Determination of molecular size variants (CE-SDS)) can also be performed using CAPEL-205.

File
Recombinant therapeutic monoclonal antibodies. Determination of product-related impurities according to USP 129 and Ch.P 3127Download application file
EQUIPMENT FOR ANALYSIS
Recombinant therapeutic monoclonal antibodies. Determination of product-related impurities according to USP 129 and Ch.P 3127 Recombinant therapeutic monoclonal antibodies. Determination of product-related impurities according to USP 129 and Ch.P 3127 - by
5/ 5stars
Recombinant therapeutic monoclonal antibodies. Determination of product-related impurities according to USP 129 and Ch.P 3127